Programmed death 1 and B and T lymphocyte attenuator immunoreceptors and their association with malignant T-lymphoproliferative disorders: Brief review

Hematological Oncology

Volumn 32, Issue 3, 2014, Pages 113-119

  Karakatsanis, Stamatis ^a   Bertsias, George ^b   Roussou, Paraskevi ^c   Boumpas, Dimitrios ^c  

^a KAT HOSPITAL   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

^c SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Immune evasion; Immunoinhibitory molecules; Malignant T cell lymphoproliferative diseases

Indexed keywords

B AND T LYMPHOCYTE ATTENUATOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; BTLA PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DOWN REGULATION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; IMMUNOSURVEILLANCE; INFECTION; LEUKEMIA; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; T CELL LEUKEMIA; T LYMPHOCYTE; ANIMAL; COMMUNICABLE DISEASE; GENETICS; IMMUNOLOGICAL MONITORING; IMMUNOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR ESCAPE;

ANIMALS; COMMUNICABLE DISEASES; HUMANS; IMMUNE SYSTEM DISEASES; LYMPHOPROLIFERATIVE DISORDERS; MONITORING, IMMUNOLOGIC; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 84921823501     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2098     Document Type: Article

References (81)

1. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107: 265-276.
2. Jaffe ES, Harris NL, Stein H, Campo E, Pileri SA, Swerdlow SH. Introduction and overview of the classification of the lymphoid neoplasms. In WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. (4th edn). Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). International Agency for Research on Cancer: Lyon, France, 2008.
3. Bennett F, Luxenberg D, Ling V, et al. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. BMJ Immunol 2003; 170: 711-718.
4. Sheppard KA, Fitz LJ, Lee JM, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett 2004; 574: 37-41.
5. Bonilla F, Oettgen H. Adaptive immunity. J Allergy Clin Immunol 2010; 125: S33-40.
6. Shinohara T, Taniwaki M, Ishida Y, Kawaichi M, Honjo T. Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics 1994; 23: 704-706.
7. Entrez Gene: PDCD1 Programmed Cell Death 1.
8. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11: 3887-3895.
9. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002; 2: 116-126.
10. Blank C, Mackensen A. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007; 56: 739-745.
11. Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996; 8: 765-772.
12. Iwai Y, Okazaki T, Nishimura H, Kawasaki A, Yagita H, Honjo T. Microanatomical localization of PD-1 in human tonsils. Immunol Lett 2002; 83: 215-220.
13. Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-1034.
14. Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 261-268.
15. Watanabe N, Gavrieli M, Sedy JR, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 2003; 4: 670-679.
16. Entrez Gene: BTLA B and T Lymphocyte Associated.
17. Derré L, Rivals JP, Jandus C, et al. BTLA mediates inhibition of human tumor-specific CD8+ T-cells that can be partially reversed by vaccination. J Clin Invest 2010; 120: 157-167.
18. Sedy JR, Gavrieli M, Potter KG, et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol 2005; 6: 90-98.
19. Riley JL, June CH. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 2005; 105: 13-21.
20. Murphy KM, Nelson CA, Šedý JR. Balancing co-stimulation and inhibition with BTLA and HVEM. Nat Rev Immunol 2006; 6: 671-681.
21. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141-151.
22. Ansari MJ, Salama AD, Chitnis T, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 2003; 198: 63-69.
23. Marengere LE, Waterhouse P, Duncan GS, Mittrücker HW, Feng GS, Mak TW. Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4. Science 1996; 272: 1170-1173.
24. Lee KM, Chuang E, Griffin M, et al. Molecular basis of T cell inactivation by CTLA-4. Science 1998; 282: 2263-2266.
25. Guntermann C, Alexander DR. CTLA-4 suppresses proximal TCR signaling in resting human CD4+ T-cells by inhibiting ZAP-70 Tyr319 phosphorylation: a potential role for tyrosine phosphatases. J Immunol 2002; 168: 4420-4429.
26. D'Souza M, Fontenot AP, Mack DG, et al. Programmed death 1 expression on HIV-specific CD4(+) T-cells is driven by viral replication and associated with T cell dysfunction. J Immunol 2007; 179: 1979-1987.
27. Zhang JY, Zhang Z, Wang X, et al. PD-1 upregulation is correlated with HIV-specific memory CD8(+) T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood 2007; 109: 4671-4678.
28. Beswick EJ, Pinchuk IV, Das S, Powell DW, Reyes VE. Expression of the programmed death ligand 1, B7-H1, on gastric epithelial cells after Helicobacter pylori exposure promotes development of CD4(+) CD25(+) FoxP3(+) regulatory T-cells. Infect Immun 2007; 75: 4334-4341.
29. Smith P, Walsh CM, Mangan NE, et al. Schistosoma mansoni worms induce anergy of T-cells via selective up-regulation of programmed death ligand 1 on macrophages. J Immunol 2004; 173: 1240-1248.
30. Lepenies B, Pfeffer K, Hurchla MA, et al. Ligation of B and T lymphocyte attenuator prevents the genesis of experimental cerebral malaria. J Immunol 2007; 179: 4093-4100.
31. Deppong C, Juehne TI, Hurchla M, et al. Cutting edge: B and T lymphocyte attenuator and programmed death receptor-1 inhibitory receptors are required for termination of acute allergic airway inflammation. J Immunol 2006; 176: 3909-3913.
32. Oya Y, Watanabe N, Owada T, et al. Development of autoimmune hepatitis-like disease and production of autoantibodies to nuclear antigens in mice lacking B and T lymphocyte attenuator. Arthritis Rheum 2008; 58: 2498-2510.
33. Liu X, Alexiou M, Martin-Orozco N, et al. Cutting edge: a critical role of B and T lymphocyte attenuator in peripheral T cell tolerance induction. J Immunol 2009; 182: 4516-4520.
34. Sun Y, Brown NK, Ruddy MJ, et al. B and T lymphocyte attenuator tempers early infection immunity. J Immunol 2009; 183: 1946-1951.
35. Ansell SM, Stenson M, Habermann TM, Jelinek DF, Witzig TE. CD4+T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol 2001; 19: 720-726.
36. Corthay A, Skovseth DK, Lundin KU, et al. Primary antitumor immune response mediated by CD4+T-cells. Immunity 2005; 22: 371-383.
37. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T-cells in the antitumor immune response. J Exp Med 1998; 188: 2357-2368.
38. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002; 298: 850-854.
39. Nishimura T, Iwakabe K, Sekimoto M, et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999; 190: 617-627.
40. Perez-Diez A, Joncker NT, Choi K, et al. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 2007; 109: 5346-5354.
41. Ding ZC, Blazar BR, Mellor AL, Munn DH, Zhou G. Chemotherapy rescues tumor-driven aberrant CD4+T-cell differentiation and restores an activated polyfunctional helper phenotype. Blood 2010; 115: 2397-2406.
42. Tang Q, Boden EK, Henriksen KJ, Bour-Jordan H, Bi M, Bluestone JA. Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur J Immunol 2004; 34: 2996-3005.
43. Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T-cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000; 12: 171-81.
44. Gorelik L, Flavell RA. Transforming growth factor-beta in T-cell biology. Nature reviews 2002; 2: 46-53.
45. Zou W. Regulatory T-cells, tumor immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307.
46. Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+T-cells in B-cell non-Hodgkin lymphoma. Blood 2006; 107: 3639-3646.
47. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA-4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T-cells. J Clin Invest 2006; 116: 1935-1945.
48. Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T-cells following therapeutic cancer vaccines. Blood 2006; 107: 628-636.
49. Hiura T, Kagamu H, Miura S, et al. Both regulatory T-cells and antitumor effector T-cells are primed in the same draining lymph nodes during tumor progression. J Immunol 2005; 175: 5058-5066.
50. + T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy. BMC Cancer 2008; 8: 57.
51. Wei S, Shreiner AB, Takeshita N, Chen L, Zou W, Chang AE. Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta. Cancer Res 2008; 68: 5432-5438.
52. Fourcade J, Sun Z, Pagliano O, et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 2012; 72: 887-896.
53. Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM. Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T-cells. Clin Cancer Res 2011; 17: 4232-4244.
54. Shimauchi T, Kabashima K, Nakashima D, et al. Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+T-cells in adult T-cell leukemia/lymphoma. Int J Cancer 2007; 121: 2585-2590.
55. Kozako T, Yoshimitsu M, Fujiwara H, et al. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia 2009; 23: 375-382.
56. Samimi S, Benoit B, Evans K, et al. Increased programmed death-1 expression on CD4+T-cells in cutaneous T-cell lymphoma: implications for immune suppression. Arch Dermatol 2010; 146: 1382-1388.
57. Juszczynski P, Ouyang J, Monti S, et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A 2007; 104: 13134-13139.
58. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T-cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004; 103: 1755-1762.
59. Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1 (PD-1) is a marker of germinal center-associated T-cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 2006; 30: 802-810.
60. Yamamoto R, Nishikori M, Kitawaki T, et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008; 111: 3220-3224.
61. Chetaille B, Bertucci F, Finetti P, et al. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 2009; 113: 2765-2775.
62. M'Hidi H, Thibult ML, Chetaille B, et al. High expression of the inhibitory receptor BTLA in T-follicular helper cells and in B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Am J Clin Pathol 2009; 132: 589-596.
63. Gertner-Dardenne J, Fauriat C, Orlanducci F, et al. The co-receptor BTLA negatively regulates human Vγ9Vδ2 T cell proliferation: a potential way of immune escape for lymphoma cells. Blood 2013; 122: 922-931.
64. Sicard H, Al Saati T, Delsol G, Fournie JJ. Synthetic phosphoantigens enhance human Vγ9Vδ2 T lymphocytes killing of non-Hodgkin's B lymphoma. Mol Med 2001; 7: 711-722.
65. Gertner J, Wiedemann A, Poupot M, Fournié JJ. Human gammadelta T lymphocytes strip and kill tumor cells simultaneously. Immunol Lett 2007; 110: 42-53.
66. Hobo W, Norde WJ, Schaap N, et al. B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T-cells in patients after allogeneic stem cell transplantation. J Immunol 2012; 189: 39-49.
67. Kozako T, Yoshimitsu M, Akimoto M, et al. Programmed death-1 (PD-1)/PD-1 ligand pathway-mediated immune responses against human T-lymphotropic virus type 1 (HTLV-1) in HTLV-1-associated myelopathy/tropical spastic paraparesis and carriers with autoimmune disorders. Hum Immunol 2011; 72: 1001-1006.
68. Haynes NM, Allen CD, Lesley R, Ansel KM, Killeen N, Cyster JG. Role of CXCR5 and CCR7 in follicular Th cell positioning and appearance of a programmed cell death gene-1high germinal center-associated subpopulation. J Immunol 2007; 179: 5099-5108.
69. Muenst S, Hoeller S, Dirnhofer S, Tzankov A. Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum Pathol 2009; 40: 1715-1722.
70. Muenst S, Hoeller S, Willi N, Dirnhofera S, Tzankov A. Diagnostic and prognostic utility of PD-1 in B cell lymphomas. Dis Markers 2010; 29: 47-53.
71. Roncador G, García Verdes-Montenegro JF, Tedoldi S, Paterson JC, Klapper W, Ballabio E, et al. Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica 2007; 92: 1059-1066.
72. Yu H, Shahsafaei A, Dorfman DM. Germinal-center T-helper-cell markers PD-1 and CXCL13 are both expressed by neoplastic cells in angioimmunoblastic T-cell lymphoma. Am J Clin Pathol 2009; 131: 33-41.
73. Baseggio L, Traverse-Glehen A, Berger F, et al. CD10 and ICOS expression by multiparametric flow cytometry in angioimmunoblastic T-cell lymphoma. Mod Pathol 2011; 24: 993-1003.
74. Nicolae A, Pittaluga S, Venkataraman G, et al. Peripheral T-cell lymphomas of follicular T-helper cell derivation with Hodgkin/Reed-Sternberg cells of B-cell lineage: both EBV-positive and EBV-negative variants exist. Am J Surg Pathol 2013; 37: 816-826.
75. Cetinözman F, Jansen PM, Willemze R. Expression of programmed death-1 in primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma. Am J Surg Pathol 2012; 36: 109-116.
76. Miyoshi H, Sato K, Niino D, et al. Clinicopathologic analysis of peripheral T-cell lymphoma, follicular variant, and comparison with angioimmunoblastic T-cell lymphoma: Bcl-6 expression might affect progression between these disorders. Am J Clin Pathol 2012; 137: 879-889.
77. Kempf W, Kazakov DV, Cipolat C, Kutzner H, Roncador G, Tomasini D. CD4/CD8 double negative mycosis fungoides with PD-1 (CD279) expression--a disease of follicular helper T-cells? Am J Dermatopathol 2012; 34: 757-761.
78. Rodríguez-Pinilla SM, Atienza L, Murillo C, et al. Peripheral T-cell lymphoma with follicular T-cell markers. Am J Surg Pathol 2008; 32: 1787-1799.
79. Ohmatsu H, Sugaya M, Fujita H, Kadono T, Sato S. Primary Cutaneous Follicular Helper T-cell Lymphoma Treated with Allogeneic Bone Marrow Transplantation: Immunohistochemical Comparison with Angioimmunoblastic T-cell Lymphoma. Acta Derm Venereol 2013 Jun 5. [Epub ahead of print]
80. Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008; 14: 3044-3051.
81. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465.